Md. biopharm gets 2 new neurodegenerative disorder treatment patents

Neuralstem Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office. One patent covers ways of treating neurodegenerative disorders through transplantation of neural stem cells. The other covers neural stem cells engineered to express IGF-1, a molecule with potential in the treatment of neurodegenerative ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.